-
Kalydeco Approved to Treat 6- to 12-month-old Infants with Cystic Fibrosis
Kalydeco has been approved in the U.S. to treat infants from six to 12 months old, who have cystic fibrosis and at least one CFTR gene mutation. Click here to read more about this news.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.